Peripheral lymphocyte CD39 expression in NSCLC patients was limited to B cells (CD19+), while low levels of CD39 expression were observed among CD4+ T cells, CD8+ T cells and NK cells (CD56+) (figure 1B). This evidence concerns the gene CD4 and non-small cell lung carcinoma.